Skip to main content
OpenTrials
Completed

NCT Number: NCT03531151

MRI of Myocardial Infarction

Heart failure (HF) is an enormous health burden affecting approximately 5.1 million people in the US and is the cause of 250,000 deaths each year. Approximately 50% of HF is caused by myocardial ischemia and requires immediate restoration of coronary blood flow to the affected myocardium. However, the success of reperfusion is partly limited by intramyocardial hemorrhage, which is the deposition of intravascular material into the myocardium. Hemorrhagic reperfusion injury has high prevalence and patients have a much greater risk of adverse left ventricular remodeling, risk of fatal arrhythmia, impaired systolic function and are hospitalized at a greater rate. Recent magnetic resonance imaging techniques have improved assessment of reperfusion injury, however, the association between MRI contrasts and reperfusion injury is highly unclear, and lacks specificity to IMH. Improved imaging of IMH and accurate knowledge about its spatial and temporal evolution may be essential for delivery of optimal medical therapy in patients and critical to identify patients most at risk for adverse ventricular remodeling. The overall goal is to investigate the magnetic properties of hemorrhage and develop MRI techniques with improved specificity to hemorrhage. New MRI techniques permit noninvasive assessment of the magnetic susceptibility of tissues and can target tissue iron. Therefore, the investigators hypothesize that MRI imaging of myocardial magnetic susceptibility can map hemorrhagic myocardium. The investigators will perform a longitudinal observational study in patients after reperfusion injury to validate these methods, compare the methods with conventional MR contrasts and develop MR methods for imaging humans.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Between the ages of 18 and 80
  • Patients must be able to read and understand English
  • Participants must sign the informed consent form
  • Elevated and delayed peak creatine kinase-MB and troponin I (cTnI) and troponin T (cTnT) in blood serum,
  • ST elevation detected on ECG

Exclusion criteria

  • contraindications to cardiac MRI, including claustrophobia
  • advanced renal disease (estimated glomerular filtration rate 30 mL/min) or hypersensitivity to gadolinium
  • presence of a cardiac pacemaker or implanted cardiac cardioverter defibrillator
  • pregnancy
  • personal or family history of hypertrophic cardiomyopathy
  • inability to provide informed consent
  • history of seizure disorder

Treatment and study plan

Primary outcomes

  1. ejection fraction

    Time frame: <36 hours to >6 months

Secondary outcomes

  1. relaxation times

    Time frame: <36 hours to >6 months

  2. extracellular volume fraction

    Time frame: <36 hours to >6 months

Sponsors and collaborators

Lead sponsor

University of Pennsylvania

Other

Registry information

Official study title

Magnetic Resonance Imaging of Myocardial Infarction

Acronym: MRIMI

Important dates

Study start
2018
Primary completion
2025
Study completion
2025
First posted
May 21, 2018
Registry last updated
Sep 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.